Retatrutide 20mg (Reusable Pen)

🧬 Retatrutide for sale– Triple Receptor Agonist for Advanced Metabolic Research

Synonyms: LY3437943, GLP-1/GIP/Glucagon Triagonist
CAS Number: 2381089-83-2
Sequence: 39-amino acid peptide (modified analog of oxyntomodulin)
Molecular Weight: ~4867.3 Da
Form: Pre-filled 20mg injectable pen
Purity: ≥98% (HPLC)
Research Use Only. This compound is not approved for human or veterinary use..

Refillable pen allowing the user just to purchase the Retatrutide cartridge when a replacement is needed saving cost and maintaining convenience.

—

Description: Retatrutide for sale
Retatrutide is a next-generation triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. This multi-pathway engagement enables a synergistic effect on appetite suppression, energy expenditure, and glycemic control. The 20mg pre-filled pen format offers precise, ready-to-administer dosing, ideal for advanced metabolic research protocols requiring consistent delivery and elevated exposure.

—

⚙️ Mechanism of Action:

retatrutide for sale mimics and amplifies the body’s natural incretin and glucagon signaling cascade:

• GLP-1R Activation: Enhances insulin secretion, delays gastric emptying, and reduces appetite
• GIPR Activation: Improves insulin sensitivity and β-cell function
• GCGR Activation: Increases energy expenditure, promotes lipolysis, and reduces hepatic steatosis

This triple-receptor synergy results in robust weight loss, improved glucose metabolism, and visceral fat reduction, making it a powerful scaffold for obesity and metabolic syndrome research.

—

📈 Research Applications:

Retatrutide is under investigation in preclinical and clinical models for:

• Obesity and body weight regulation
• Type 2 diabetes and insulin resistance
• Non-alcoholic fatty liver disease (NAFLD)
• Cardiometabolic risk reduction
• Combination therapy with amylin analogs (e.g., Cagrilintide)

In Phase 2 trials, subjects receiving high-dose Retatrutide experienced up to 24.2% body weight reduction over 48 weeks, with favorable shifts in lipid and glycemic markers.

—

🧪 Dosing & Handling (Preclinical):

• Formulation: 20mg pre-filled pen
• Half-life: ~6–7 days (supports once-weekly administration)
• Storage: Refrigerate at 2–8°C; protect from light
• Administration: Subcutaneous injection; rotate sites to minimize irritation
• Cycle: 12–24 weeks typical for metabolic remodelling studies

—

📦 Packaging & Handling:

Supplied as a sterile, pre-filled 20mg pen for subcutaneous administration. Store refrigerated 2–8°C. Do not freeze. Use aseptic technique. For research use only.